- Home
- SKYE vs CPHC Comparison
SKYE vs CPHC Comparison
Compare SKYE & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- CPHC
- Stock Information
- Founded
- SKYE 2012
- CPHC 1994
- Country
- SKYE United States
- CPHC United States
- Employees
- SKYE N/A
- CPHC N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- SKYE Health Care
- CPHC Consumer Discretionary
- Exchange
- SKYE Nasdaq
- CPHC Nasdaq
- Market Cap
- SKYE 80.7M
- CPHC 85.7M
- IPO Year
- SKYE N/A
- CPHC 1994
- Fundamental
- Price
- SKYE $1.81
- CPHC $17.38
- Analyst Decision
- SKYE Buy
- CPHC
- Analyst Count
- SKYE 6
- CPHC 0
- Target Price
- SKYE $16.60
- CPHC N/A
- AVG Volume (30 Days)
- SKYE 1.7M
- CPHC 1.5K
- Earning Date
- SKYE 05-08-2025
- CPHC 05-08-2025
- Dividend Yield
- SKYE N/A
- CPHC 1.65%
- EPS Growth
- SKYE N/A
- CPHC N/A
- EPS
- SKYE N/A
- CPHC 0.16
- Revenue
- SKYE N/A
- CPHC $60,605,931.00
- Revenue This Year
- SKYE N/A
- CPHC N/A
- Revenue Next Year
- SKYE N/A
- CPHC N/A
- P/E Ratio
- SKYE N/A
- CPHC $106.06
- Revenue Growth
- SKYE N/A
- CPHC 0.20
- 52 Week Low
- SKYE $1.14
- CPHC $16.91
- 52 Week High
- SKYE $13.49
- CPHC $24.07
- Technical
- Relative Strength Index (RSI)
- SKYE 48.48
- CPHC 45.70
- Support Level
- SKYE $1.36
- CPHC $17.00
- Resistance Level
- SKYE $2.30
- CPHC $17.69
- Average True Range (ATR)
- SKYE 0.21
- CPHC 0.15
- MACD
- SKYE 0.02
- CPHC 0.08
- Stochastic Oscillator
- SKYE 42.35
- CPHC 60.26
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.